| Purpose of the guideline: |
Migraine is a highly disabling neurological disorder that affects over 1 billion people globally. Migraines are characterized by severe pain and may be accompanied by symptoms such as nausea, vomiting, photophobia and phonophobia, significantly impacting work and daily life. Current treatment methods include acute treatment and preventive treatment. The goal of acute treatment is to rapidly and sustainably alleviate pain and migraine-related symptoms, which is particularly important for improving the quality of life. However, excessive use of acute treatments or addictive acute treatment medications may lead to medication overuse headache, further contributing to chronic and refractory headaches. Additionally, there is currently a lack of standardized acute treatment guidelines for specific patient populations in China. In recent years, with the continuous development of new medications and the emergence of neurostimulation therapies, novel acute treatment approaches for migraines have emerged. Therefore, Chinese Medical Doctor Association and Chinese Research Hospital Association jointly initiated the development of these guidelines for acute migraine treatment, aiming to provide a basis for standardizing migraine treatment. |
